Original Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. May 7, 2012; 18(17): 2035-2042
Published online May 7, 2012. doi: 10.3748/wjg.v18.i17.2035
Figure 1
Figure 1 Susceptibilities of various human hepatocyte (MIHA) and hepatocellular carcinoma cells (Hep3B, PLC, Huh7, HepG2, and Bel7404) to transforming growth factor-β. A: Cells were treated with 5 ng/mL transforming growth factor (TGF)-β1 for 96 h and cell survival was then determined by methylthiazoletetrazolium assays; B: Nuclear morphology of apoptotic TGF-β-treated Hep3B cells demonstrated by 4’,6-Diamidino-2-phenylindole staining and examined by fluorescence microscopy. Scale bar: 50 μm, 400 ×.